$MESO

In 2024-2026, longevity advancements include FDA-approved MSC products, accelerated peptide approvals, and AI-designed drugs. GLP-1 medicines show cardiometabolic benefits. A gray market of wellness peptides exists, with FDA advisory votes on compounding. Mesoblast's Ryoncil gained FDA approval, and Longeveron's Laromestrocel targets aging-related conditions. Life Biosciences initiated a partial cellular reprogramming trial. Key players include Altos Labs, NewLimit, and Life Biosciences, with va

Mesoblast is conducting trials for RYONCIL in acute GVHD and Duchenne muscular dystrophy, with results expected in 2027. The company anticipates double-digit revenue growth and is pursuing approvals for rexlemestrocel-L in chronic low back pain and REVASCOR in heart failure. Mesoblast expects lower cash burn in fiscal 2027 and has a $125M credit facility.

MESOBLAST LTD (MESO) furnished an SEC Form 6-K — earnings release. MESOBLAST REPORTS SUBSTANTIAL REVENUE GROWTH TO US$120M RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 New York, USA: August 26 and Melbourne, Australia: August 27, 2026: Mesobla

Mesoblast (MESO) shares rose about 9.5% after the company said it completed patient treatment in the MSB-DR004 pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain from degenerative disc disease. The trial enrolled 350 patients versus 300 planned. The primary endpoint targets durable pain reduction at 12 months, with FDA RMAT designation and a BLA submission targeted for Q3 2027.

Mesoblast Limited (Nasdaq:MESO) said it reached its target of at least 300 treated patients in the MSB-DR004 pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain due to degenerative disc disease. The primary endpoint compares pain reduction at 12 months vs sham. Top-line results are expected mid-2027.

Australia’s S&P/ASX 200 fell 0.41% to 8,770.2 by midday Monday as Middle East tensions and IMF warnings weighed on sentiment. The IMF cut Australia’s 2026 growth forecast to 1.9% and flagged inflation near 4%. Coles slid on a reported Greencross deal; Santos and Woodside were softer; Mesoblast was upgraded to buy with a $4.45 target.

ASX futures pointed to a 0.49% rise at the open after Wall Street ended higher, supported by AI and chip stocks. The ASX 200 rose 0.5% on Friday to 8,806, led by mining and financials. Telstra fell 1.6%, WiseTech 1.8%, while Mesoblast rose 6% on US$115m FY2026 revenue. Geopolitical Iran tensions and oil moves weighed on sentiment.

Mesoblast Limited (Nasdaq:MESO) reported Ryoncil net revenue of $36 million for the quarter ended June 30, 2026, and $115 million for the full fiscal year. The company said revenues exceeded initial projections and expects continued growth, citing uptake in major U.S. pediatric centers. Results are preliminary pending audit.

Mesoblast (MESO) stock is gaining attention due to strong Q1 2026 sales of Ryoncil, reaching $30.3 million and nearing $100 million in cumulative revenue. The FDA's Investigational New Drug clearance for Ryoncil in Duchenne muscular dystrophy is seen as a significant breakthrough, paving the way for a registrational trial. Insider purchases and institutional activity also reflect growing confidence, with Wall Street analysts issuing "Buy" ratings.

Mesoblast has received FDA Investigational New Drug (IND) clearance to directly proceed with a registrational trial for Ryoncil in Duchenne muscular dystrophy (DMD). The trial will enroll 76 patients aged 5-9, with time-to-stand at nine months as the primary endpoint. This builds on Ryoncil's existing pediatric safety profile, preclinical efficacy in DMD models, and an FDA-approved manufacturing process.